Antibiotics for treatment of resistant gram-positive coccal infections

Indian Journal of Pediatrics

Volumn 73, Issue 4, 2006, Pages 323-334

  Al Tatari, Hossam ^b   Abdel Haq, Nahed ^b   Chearskul, Pimpanada ^b   Asmar, Basim ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

Antibacterial agents; Bacterial infections; Vancomycin,Gram positive

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEFAZOLIN; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN; CISAPRIDE; CLOXACILLIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DIGOXIN; FLUCLOXACILLIN; ITRACONAZOLE; KETOCONAZOLE; LINEZOLID; MIDAZOLAM; NAFCILLIN; OXACILLIN; PENICILLIN G; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; QUINOLONE; RAPAMYCIN; TACROLIMUS; TELITHROMYCIN; THEOPHYLLINE; TIGECYCLINE; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; KETOLIDE; MINOCYCLINE;

AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BACTERIAL INFECTION; BELL PALSY; BONE MARROW SUPPRESSION; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEADACHE; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MUSCLE CRAMP; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; PAIN; PRURITUS; RASH; SINUSITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; SWELLING; THROMBOCYTOPENIA; VOMITING; ANTIBIOTIC RESISTANCE; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KETOLIDES; MINOCYCLINE; PEPTIDES, CYCLIC;

EID: 33746864112     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02825827     Document Type: Conference Paper

References (118)

1. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrobial Agents & Chemotherapy 1998; 42(5) : 1303-1304.
2. Summary of notifiable diseases, United States 1994. MMWR Morb Mortal Wkly Rep 1994; 43(53) : 1-80.
3. Novak R. Henriques B, Charpentier E. Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae [see comments]. Nature 1999; 399(6736) : 590-593.
4. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Bank JD, White E, Jarvis WR. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. [comment]. New England Journal of Medicine 1999; 340(7) : 493-501.
5. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR - Morbidity & Mortality Weekly Report 2002; 51(26) : 565-567.
6. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis [see comments]. Annals of Internal Medicine 1991; 115(9) : 674-680.
7. Fowler VGJ, Kong LK, Corey GR, Gottlieb GS, McClelland, RS, Sexton DJ, Gesty-Palmer D, Harrell LJ. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. Journal of Infectious Diseases 1999; 179(5): 1157-1161.
8. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clinical Infectious Diseases 1999; 29(5) : 1171-1177.
9. Vasquez D. The streptogramin family of antibiotics. In: Gottlieb D, Shaw PD, eds. Antibiotics. New York: Springer-Verlag, 1967; 387-403.
10. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid) tested against over 28,000 recent clinical isolates from 200 medical enters in the United States and Canada. Diagn Microbial Infect Dis 1998; 31 : 437-451.
11. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in animal infection model. In Program and abstracts of the thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy : 1993, Ernest N. Moprial Convention Center, New Orleans, Louisiana. Washington, D.C. American Society for Microbiology, 1993.
12. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemotherapy 1999; 44 : 251-261.
13. Synercid [annotated package insert]. Parsippany, N.J.: Aventis Pharmaceuticals, 1999.
14. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicoated studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemotherapy 1999; 44 : 263-273.
15. Raad I, Bompart F. Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18 : 199-202.
16. Brickner SJ. Oxazolidinone antibacterial agents. Current Pharmaceutical Design 1996;2:175-94.
17. Ford C, Hamel J, Stapert D, Moerman J, Hutchinson D, Barbachyn M et al. Oxazolidinones: a new class of antimicrobials. Infections in Medicine 1999; 16 : 435-445.
18. Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1988; 32 : 1341-1346.
19. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41 : 2127-2131.
20. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42 : 3251-325.
21. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus [Letter]. Lancet 2001; 358 : 207-208.
22. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [Letter]. Lancet 2001; 357 : 1179-1179.
23. Zurenko G, Todd WM, Hafkin BA. Development of linezolid-resistant Enterococcus faecium in two compassionate use programs patients treated with linezolid [Abstract]. In Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999, San Francisco, California. Washington, DC: American Soc for Microbiology; 1999. Abstract no. 848.
24. Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn; 2000.
25. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000; 59 : 7-16.
26. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40 : 839-845.
27. Brown BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activity of linezolid against multiple species of Nocardia : a new drug of choice for a difficult disease? In Program and Abstracts of the 100th General Meeting of the American Society for Microbiology, 2000, Los Angeles, California. Washington, DC: American Soc for Microbiology; 2000. Abstract no. U-57.
28. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady MA et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis [Abstract]. In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy , 24-27 September 1998, San Diego, California. Washington, DC: American Soc for Microbiology; 1998. Abstract no. A-54.
29. Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Clin Infect Dis 2000;31(suppl 4):144-9.
30. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM et al. Randomized comparison of linezolid (PNU-100766) vs oxacillin- dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44 : 3408-13.
31. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32 : 402-412.
32. Cammarata SK, San Pedro GS, Timm JA, Hempsall KA, Todd WM, Oliphant TH et al. Comparison of Linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [Abstract]. In: Abstracts of the European Congress of Clinical Microbiology and Infectious Diseases, 28-31 May 2000, Stockholm, Sweden.
33. Hyatt JM, Ballow CH, Forrest A, Turnak MR, Stalker DJ, Schentag JJ. Safety and efficacy of linezolid in the eradication of nasal Staphylococcus aureus . In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 September 1998, San Diego, California. Washington, DC: American Soc for Microbiology; 1998. Abstract no. A-4.
34. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin- dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066.
35. Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid agaist vancomycin resistant staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. AntimicrobAgents Chemother 2003; 47: 3960-3963.
36. Snydman DR, Jacobus NV, McDermott LA et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000; 44: 3447-3450.
37. Vaudaux P, Francois P, Bisognano C et al. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to staphylococcus aureus. J Antimicrob Chemother 2003; 52: 89-95.
38. Hermsen ED, Hovde LB, Hotchkiss JR et al. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003; 47: 3764-3767.
39. Thorne GM, Alder J. Daptomycin: A novel lipopeptide antibiotic. Clin Microbiol Newsletter 2002; 24: 33-40.
40. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49 : 467-470.
41. Cubicin product package insert. Lenington MA, USA; Cubist Pharmaceuticals, Inc. September 2003
42. Critchley IA, Blosser-Middleton RS, Jones ME et al. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003; 47: 1689-1693.
43. Critchley IA, Draghi DC, Sahm DF et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51: 639-649.
44. Richter SS, Kealey DE, Murray CT et al. The in vitro activity of daptomycin against staphylococcus aureus and enterococcus species. J Antimicrob Chemother 2003; 52: 123-127.
45. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
46. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45: 1919-1922.
47. King A, Phillips I. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001; 48: 219-223.
48. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48: 563-567.
49. National PBM Drug Monograph. Daptomycin (CubicinTM). VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Available at http://www.pbm.va.gov/monograph/110280daptomycin.pdf
50. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48 : 563-567.
51. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066.
52. Cha R, Grucz RG, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-1603.
53. Bozdogan B, Esel D, Whitener C et al. Antibacteria susceptibility of a vancomycin-resistant styaphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52 : 864-868.
54. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant staphylococcus aureus containing the vanA resistance gene. New Engl J Med 2003; 348 : 1342-1347.
55. Sun HK, Kuti JL, Nicolau DP. Daptomycin a novel lipopeptide antibiotic for the treatment of resistant gram-positive infections. Formulary 2003; 38: 634-645.
56. Dvorchik BH, Brazier, D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323.
57. Wise R, Gee T, Andrews JM et al. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46: 31-33.
58. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000 Dec; 6(12) : 661-669.
59. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol 1998 Dec; 37(6) : 418-425.
60. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000 Apr; 36(1) : 183-93.
61. Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998 Aug; 42(8):2138-40.
62. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1999 Sep;35(1):37-44.
63. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J Antimicrob Chemother 2003 Mar;51(3):497-511
64. Hoppe JE, Bryskier A. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 1998 Apr;42(4) : 965-966.
65. Bebear CM, Renaudin H, Bryskier A, Bebear C. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000 Jul; 44(7) : 1980-2.
66. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998 Jun; 42(6) : 1515-1516.
67. Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999 Jan; 43(1):90-5.
68. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61(6) : 815-829.
69. Barry AL, Fuchs PC, Brown SD. Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci. Eur J Clin Microbiol Infect Dis 2001 Jul; 20(7) : 494-497.
70. Gustafsson I, Engstrand L, Cars O. In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori. Antimicrob Agents Chemother 2001 Jan; 45(1) : 353-355.
71. Rolain JM, Maurin M, Bryskier A, Raoult D. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob Agents Chemother 2000 May; 44(5) : 1391-1393.
72. Bhargava V, Lenfant B, Perret C, Pascual MH, Sultan E, Montay G. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 2002; 34(11) : 823-826.
73. Namour F, Wessels DH, Pascual MH, Reynolds D, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001 Jan; 45(1) : 170-175.
74. Gehanno P, Sultan E, Passot V, Nabet P, Danon J, Romanet P, Attal P. Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy. Int J Antimicrob Agents 2003 May; 21(5) : 441-445.
75. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ. The ketolides: a critical review. Drugs 2002; 62(12) : 1771-804.
76. Drusano G. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin Microbiol Infect 2001; 7 Suppl 3:24-9.
77. Bearden DT, Neuhauser MM, Garey KW. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 2001 Oct; 21(10) : 1204-1222.
78. Zhanel GG, Hoban DJ. Ketolides in the treatment of respiratory infections. Expert Opin Pharmacother 2002 Mar; 3(3) : 277-297.
79. Johnson AP. Telithromycin. Aventis Pharma. Curr Opin Investig Drugs 2001 Dec; 2(12):1691-701.
80. Norrby SR, Rabie WJ, Bacart P, Mueller O, Leroy B, Rangaraju M, Butticaz-Iroudayassamy E. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis 2001; 33(12) : 883-890.
81. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26 : 704-714.
82. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial [abstract L-739]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) . Washington, DC: American Society for Microbiology, 2003:416.
83. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1 : 464-469.
84. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64 : 63-88.
85. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20 : 219S-23S.
86. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
87. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44 : 943-949.
88. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40 : 173-177.
89. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002; 46 : 892-895.
90. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44 : 2747-51.
91. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47 : 400-404.
92. Fritsche TR, Sader HS, Kirby JT, Jones RN. In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary staphylococci, streptococci and enterococci [abstract P937]. In Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical Microbiology and Infectious Diseases 2004: 246.
93. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003; 52 : 138-139.
94. Low DE, Kreiswirth BN, Weiss K, Willey BM. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents 2002; 20 : 220-222.
95. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000; 44 : 2225-229.
96. Kitzis MD, Ly A, Goldstein FW. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48 : 366-367.
97. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Rresults of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47 : 1867-1874.
98. Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004; 48 : 323-325.
99. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38 : 177-179.
100. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46 : 2595-2601.
101. Gales AC, Silva JB, Andrade SS, Sader HS, Jones RN. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from the Latin American region [abstract E-1537]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003 : 257.
102. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-tbutylglycylamido- minocycline) susceptibility test development for streptococci, Haemophilus influenzae, and Neisseria gonorrhoeae: preliminary guidelines and interpretive
103. Johnson B, Stevens T, Bouchillon S et al. Tigecycline (GAR-936) a novel glycylcycline with promising anti-staphylococcal activity [abstract E-1536]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003 : 257.
104. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52 : 864-868.
105. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50 : 758-759.
106. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49 : 479-487.
107. Cercenado E, Cercenado S, Bouza E. In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother 2003; 47 : 2644-2645.
108. Johnson B, Stevens T, Bouchillon S et al. In vitro study of tigecycline against 776 clinical isolates of non-Enterobacteriaceae from hospitals across Europe [abstract 3311]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology , 2003; 206.
109. Johnson B, Stevens T, Bouchillon S et al. In vitro antibacterial activity of tigecycline a novel glycylcycline against clinical isolates of Enterobacteriaceae [abstract 3464]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology , 2003 : 206-207.
110. Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6 : 159-63.
111. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46 : 31643167.
112. Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis 2002; 42 : 145-147.
113. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis . Int J Antimicrob Agents 2000;16 : 61-63.
114. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after a single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49 : 220-229.
115. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:5.
116. Meagher AK, Cirincione BB, Liolios KA, Troy S, Ambrose PG. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment [abstract P1023]. In Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague). Basel: European Society of Clinical.
117. Tombs NL. Tissue distribution of Gar-936, a broad-spectrum antibiotic, in male rats. In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:26.
118. Fang GD, Weiss WJ, Scheld WM. Comparative efficacy of GAR-936 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits [abstract 868]. In Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000; 51.